Printer Friendly

HHS cancels UCSF contract for research involving human fetal tissue from elective abortions: "Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trump S administration".

The Washington Post (predictably) headlined the move, "Trump administration imposes new restrictions on fetal tissue research."

A more measured and accurate statement is that upon review, the Administration is taking additional steps to ensure that the National Institutes of Health (NIH) will not be funding its own research that uses tissue from elective abortions and will continue to pursue development of ethical alternatives.

In a six-paragraph explanation, HHS noted that last September

   the Department of
   Health and Human
   Services (HHS) terminated
   a contract
   between Advanced
   Bioscience Resources,
   Inc. and the Food and
   Drug Administration
   that provided human
   fetal tissue from elective
   abortions to develop
   testing protocols.
   The Department was
   not sufficiently assured
   that contract included
   the appropriate protections
   applicable to
   fetal tissue research or
   met all other procurement
   require-ments.
   As a result, HHS also
   initiated a comprehensive
   review of all HHS
   research involving human
   fetal tissue from
   elective abortions to
   ensure consistency
   with statutes and regulations
   governing such
   research, and to ensure
   the adequacy of procedures
   and oversight of
   this research in light of
   the serious regulatory,
   moral, and ethical considerations
   involved.

      When the audit and
   review began, HHS had
   an existing contract
   with the University
   of California, San
   Francisco (UCSF)
   regarding research
   involving human fetal
   tissue from elective
   abortions. HHS has
   been extending the
   UCSF contract by
   means of 90-day
   extensions while
   conducting its audit
   and review. The
   current extension
   expires on June 5,
   2019, and there will be
   no further extensions.

With that as backdrop, HHS went on to add to put the decision in context:

   Promoting the dignity
   of human life from
   conception to natural
   death is one of the
   very top priorities of
   President Trump's
   administration. The
   audit and review
   helped inform the
   policy process that led
   to the administration's
   decision to let
   the contract with
   UCSF expire and to
   discontinue intramural
   research--research
   conducted within the
   National Institutes
   of Health (NIH)--involving
   the use of
   human fetal tissue
   from elective abortion.
   Intramural research
   that requires new
   acquisition of fetal
   tissue from elective
   abortions will not be
   conducted.

HHS has already begun a review of whether there are "adequate alternatives" in HHS-funded research and "will ensure that efforts to develop such alternatives are funded and accelerated."

   In December 2018,
   NIH announced a
   $20 million funding
   opportunity for research
   to develop,
   demonstrate, and
   validate experimental
   models that do
   not rely on human
   fetal tissue from elective
   abortions. HHS
   is committed to providing
   additional
   funding to support
   the development and
   validation of alternative
   models.

Congratulations to President Trump and HHS Secretary Alex M. Azar.

COPYRIGHT 2019 National Right to Life Committee, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Andrusko, Dave
Publication:National Right to Life News
Date:Jun 1, 2019
Words:425
Previous Article:House Republicans unable to override North Carolina pro-abortion Gov. Cooper's veto of "born alive" legislation.
Next Article:Federal Judge hears closing arguments in pro-abortion challenge to four Virginia abortion laws.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |